FDA Approves KLYGEFA™ (gefurulimab-gaks), Expanding Treatment Options for Generalized Myasthenia Gravis

KLYGEFA™ (gefurulimab-gaks), is the first and only dual-binding nanobody C5 inhibitor approved for generalized myasthenia gravis (gMG).


New York, Nov. 16, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today applauded the U.S. Food and Drug Administration (FDA) approval of KLYGEFA™ (gefurulimab-gaks), a new treatment from Alexion, AstraZeneca Rare Disease for people living with generalized myasthenia gravis (gMG). This milestone represents an important advancement for the gMG community, expanding therapeutic options for a complex and often debilitating neuromuscular disease. Read Alexion, AstraZeneca Rare Disease’s press release here.

Generalized myasthenia gravis is a chronic autoimmune disorder characterized by muscle weakness that can significantly impact daily activities, including breathing, mobility, and communication. While recent progress has improved outcomes, many people continue to face challenges in achieving sustained symptom control.

“Today’s approval represents meaningful progress for people living with generalized myasthenia gravis,” said Angela Lek, PhD, Chief Research Officer, Muscular Dystrophy Association. “Each new therapy brings us closer to more personalized and effective treatment approaches, offering renewed hope for improved quality of life and long-term disease management. We are encouraged by continued innovation that addresses the underlying biology of this disease.”

KLYGEFA™ (gefurulimab-gaks), is the first and only dual-binding nanobody C5 inhibitor approved for gMG. It works by targeting key pathways involved in the immune system’s attack on the neuromuscular junction, helping to reduce the severity of symptoms associated with gMG. Data from the Phase III PREVAIL clinical trial demonstrated improvement from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at week 26 compared to placebo. A clinically meaningful improvement was observed as early as week one and sustained through week 26.  Additionally, the therapy is administered with a once-weekly subcutaneous, self-administered autoinjector, offering a convenient treatment option for people with gMG.

“Seeing the MG treatment landscape evolve from limited options to multiple targeted therapies has been an extraordinary shift for the community,” said Elizabeth Madole, MDA Ambassador living with myasthenia gravis. “Every new treatment option brings renewed hope and the possibility of finding approaches that work better for more people living with this disease. And for a kid like me, that could mean getting through a whole day of school and still having enough energy to hang out with my friends afterward. That’s what makes me hopeful.”

“Treatment goals in myasthenia gravis are evolving beyond symptom control toward helping patients return to productive lives, maximizing quality of life, reducing treatment burden, and increasing therapeutic autonomy. The approval of KLYGEFA™ (gefurulimab-gaks), is another important step towards these goals, and we look forward to seeing how it performs in clinical practice,” said Ali A. Habib, MD, Clinical Professor, Neurology, School of Medicine, UCI Health, an MDA Care Center, where he runs the myasthenia gravis (MG) clinic and is the Principal Investigator for most MG trials.

Industry Update Webinars
Families and clinicians can learn more about KLYGEFA™ (gefurulimab-gaks), during Alexion, AstraZenca Rare Disease’s upcoming Industry Update Webinar on Tuesday, December 8, 2026.

About Myasthenia Gravis
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that causes fluctuating muscle weakness. Most people with MG have generalized MG (gMG), in which weakness can affect muscles throughout the body, including those responsible for movement, swallowing, and breathing. MG can occur at any age and affects approximately 37 people per 100,000 in the United States.

MDA’s Foundational Research
Today’s approval underscores the organization’s enduring role in advancing therapies for neuromuscular diseases. Since its inception, MDA has invested more than $1.2 billion in research, including more than $57 million in MG research.   

MDA Care Center Network
Beyond research, MDA drives progress through its educational resources, advocacy efforts, and nationwide MDA Care Center Network at over 150 top medical institutions, as well as the MDA Resource Center and Gene Therapy Support Network, which provide guidance and support for families living with myasthenia gravis and more than 300 related neuromuscular conditions. For the gMG community, this milestone represents not only scientific progress, but also a testament to resilience, hope, and renewed possibility.

MDA Resource Center
For more information on myasthenia gravis, and ongoing support for families and medical professionals, contact the MDA Resource Center by phone 1-833-ASK-MDA1 (1-833-275-6321) or email ResourceCenter@mdausa.org.

Media inquiries, contact press@mdausa.org. 

About Muscular Dystrophy Association 
Muscular Dystrophy Association (MDA) has been at the center of progress for people living with muscular dystrophy, ALS, and over 300 other neuromuscular conditions for 75 years. We unite researchers, clinicians, advocates, and families to speed the pace of discovery, improve access to expert care, and ensure inclusion in every aspect of life. Our mission is simple: give the people we serve the tools and opportunities to live longer, more independent lives. To learn more visit mda.org. Follow MDA on social media on Instagram, Facebook, X, Threads, Bluesky, TikTok, LinkedIn, and YouTube. 

Attachment

 
FDA Approves KLYGEFA™ (gefurulimab-gaks), Expanding Treatment Options for Generalized Myasthenia Gravis

Coordonnées

GlobeNewswire